Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Ligand (LGND) Breakout! -- Ignore unavailable to you. Want to Upgrade?

To: WTDEC who wrote (21945)	6/6/1998 10:00:00 PM
From: Henry Niman	Respond to of 32384

Walter, I don't even think that last minute edits are an issue. It's always hard to pin down the exact publication date, even after everything is completed and the paper is accepted for publication.

To: WTDEC who wrote (21945)	6/7/1998 10:07:00 AM
From: Biotech Jim	Read Replies (2) \| Respond to of 32384

Having published in Science, the reports or articles are not accepted until the final revisions are made no matter how minor. So, if the small molecule agonist paper is still at the minor revision stage (or was at the time of the annual meeting), it could not be considered as accepted or in press. It would be foolhardy to state that a paper was in press before officially so, and could be quite embarrassing. I am also led to believe that at the time of the Tahoe presentation that the work was not yet submitted. It is usually about two months from acceptance to publication date in Science. BJ